Oral Controlled Release Drug Delivery Technology Market , by Dosage Form (Solid Dosage Forms, Semisolid, Liquid), Drug Release (Diffusion Controlled Release System, Dissolution Controlled Release System, Osmotically Controlled Release System, Dissolution And Diffusion Controlled Release System, Ion Exchange Resins Controlled Release, Hydro-Dynamically Balanced Drug Delivery System, Others): Global Opportunity Analysis and Industry Forecast, 2020-2027

1. RESEARCH METHODOLOGY

• 1.1. Desk Research

• 1.2. Real time insights and validation

• 1.3. Forecast model

• 1.4. Assumptions and forecast parameters

• 1.5. Market size estimation

  • 1.5.1. Top-down approach

  • 1.5.2. Bottom-up approach

2. REPORT SCOPE

• 2.1. Market definition

• 2.2. Key objectives of the study

• 2.3. Report overview

• 2.4. Market segmentation

• 2.5. Overview of the impact of COVID-19 on Global Oral Controlled Release Drug Delivery Technology Market 

3. EXECUTIVE SUMMARY

4. MARKET OVERVIEW

• 4.1. Introduction

• 4.2. Growth impact forces

  • 4.2.1. Drivers

  • 4.2.2. Restraints

  • 4.2.3. Opportunities

• 4.3. Market value chain analysis

  • 4.3.1. List of raw material suppliers

  • 4.3.2. List of manufacturers

  • 4.3.3. List of distributors

• 4.4. Innovation & sustainability matrices

  • 4.4.1. Technology matrix

  • 4.4.2. Regulatory matrix

• 4.5. Porter’s five forces analysis

  • 4.5.1. Bargaining power of suppliers

  • 4.5.2. Bargaining power of consumers

  • 4.5.3. Threat of substitutes

  • 4.5.4. Threat of new entrants

  • 4.5.5. Competitive rivalry intensity

• 4.6. PESTLE analysis

  • 4.6.1. Political

  • 4.6.2. Economical

  • 4.6.3. Social

  • 4.6.4. Technological

  • 4.6.5. Environmental

• 4.7. Impact of COVID-19 on Oral Controlled Release Drug Delivery Technology Market 

  • 4.7.1. Pre-covid market scenario

  • 4.7.2. Post-covid market scenario

5. Oral Controlled Release Drug Delivery Technology Market , By Disease Type

• 5.1. Overview

• 5.2 Solid Dosage Forms

  • 5.2.1 Definition, key trends, growth factors, and opportunities

  • 5.2.2 Market size analysis, by region, 2020-2027

  • 5.2.3 Market share analysis, by country, 2020-2027

• 5.3 Semisolid

  • 5.3.1 Definition, key trends, growth factors, and opportunities

  • 5.3.2 Market size analysis, by region, 2020-2027

  • 5.3.3 Market share analysis, by country, 2020-2027

• 5.4 Liquid

  • 5.4.1 Definition, key trends, growth factors, and opportunities

  • 5.4.2 Market size analysis, by region, 2020-2027

  • 5.4.3 Market share analysis, by country, 2020-2027

• 5.5 Research Dive Exclusive Insights

  • 5.5.1 Market attractiveness

  • 5.5.2 Competition heatmap

6. Oral Controlled Release Drug Delivery Technology Market , By Model

• 6.1. Overview

• 6.2 Diffusion Controlled Release System

  • 6.2.1 Definition, key trends, growth factors, and opportunities

  • 6.2.2 Market size analysis, by region, 2020-2027

  • 6.2.3 Market share analysis, by country, 2020-2027

• 6.3 Dissolution Controlled Release System

  • 6.3.1 Definition, key trends, growth factors, and opportunities

  • 6.3.2 Market size analysis, by region, 2020-2027

  • 6.3.3 Market share analysis, by country, 2020-2027

• 6.4 Osmotically Controlled Release System

  • 6.4.1 Definition, key trends, growth factors, and opportunities

  • 6.4.2 Market size analysis, by region, 2020-2027

  • 6.4.3 Market share analysis, by country, 2020-2027

• 6.5 Dissolution And Diffusion Controlled Release System

  • 6.5.1 Definition, key trends, growth factors, and opportunities

  • 6.5.2 Market size analysis, by region, 2020-2027

  • 6.5.3 Market share analysis, by country, 2020-2027

• 6.6 Ion Exchange Resins Controlled Release

  • 6.6.1 Definition, key trends, growth factors, and opportunities

  • 6.6.2 Market size analysis, by region, 2020-2027

  • 6.6.3 Market share analysis, by country, 2020-2027

• 6.7 Hydro-Dynamically Balanced Drug Delivery System

  • 6.7.1 Definition, key trends, growth factors, and opportunities

  • 6.7.2 Market size analysis, by region, 2020-2027

  • 6.7.3 Market share analysis, by country, 2020-2027

• 6.8 Others

  • 6.8.1 Definition, key trends, growth factors, and opportunities

  • 6.8.2 Market size analysis, by region, 2020-2027

  • 6.8.3 Market share analysis, by country, 2020-2027

• 6.9 Research Dive Exclusive Insights

  • 6.9.1 Market attractiveness

  • 6.9.2 Competition heatmap

7. Oral Controlled Release Drug Delivery Technology Market , By Region

• 7.1 North America

  • 7.1.1 U.S

    • 7.1.1.1 Market size analysis, By Disease Type, 2020-2027

    • 7.1.1.2 Market size analysis, By Model, 2020-2027

  • 7.1.2 Canada

    • 7.1.2.1 Market size analysis, By Disease Type, 2020-2027

    • 7.1.2.2 Market size analysis, By Model, 2020-2027

  • 7.1.3 Mexico

    • 7.1.3.1 Market size analysis, By Disease Type, 2020-2027

    • 7.1.3.2 Market size analysis, By Model, 2020-2027

  • 7.1.4 Research Dive Exclusive Insights

    • 7.1.4.1 Market attractiveness

    • 7.1.4.2 Competition heatmap

• 7.2 Europe

  • 7.2.1 Germany

    • 7.2.1.1 Market size analysis, By Disease Type, 2020-2027

    • 7.2.1.2 Market size analysis, By Model, 2020-2027

  • 7.2.2 UK

    • 7.2.2.1 Market size analysis, By Disease Type, 2020-2027

    • 7.2.2.2 Market size analysis, By Model, 2020-2027

  • 7.2.3 France

    • 7.2.3.1 Market size analysis, By Disease Type, 2020-2027

    • 7.2.3.2 Market size analysis, By Model, 2020-2027

  • 7.2.4 Spain

    • 7.2.4.1 Market size analysis, By Disease Type, 2020-2027

    • 7.2.4.2 Market size analysis, By Model, 2020-2027

  • 7.2.5 Italy

    • 7.2.5.1 Market size analysis, By Disease Type, 2020-2027

    • 7.2.5.2 Market size analysis, By Model, 2020-2027

  • 7.2.6 Rest of Europe

    • 7.2.6.1 Market size analysis, By Disease Type, 2020-2027

    • 7.2.6.2 Market size analysis, By Model, 2020-2027

  • 7.2.7 Research Dive Exclusive Insights

    • 7.2.7.1 Market attractiveness

    • 7.2.7.2 Competition heatmap

• 7.3 Asia-Pacific

  • 7.3.1 China

    • 7.3.1.1 Market size analysis, By Disease Type, 2020-2027

    • 7.3.1.2 Market size analysis, By Model, 2020-2027

  • 7.3.2 Japan

    • 7.3.2.1 Market size analysis, By Disease Type, 2020-2027

    • 7.3.2.2 Market size analysis, By Model, 2020-2027

  • 7.3.3 India

    • 7.3.3.1 Market size analysis, By Disease Type, 2020-2027

    • 7.3.3.2 Market size analysis, By Model, 2020-2027

  • 7.3.4 Australia

    • 7.3.4.1 Market size analysis, By Disease Type, 2020-2027

    • 7.3.4.2 Market size analysis, By Model, 2020-2027

  • 7.3.5 South Korea

    • 7.3.5.1 Market size analysis, By Disease Type, 2020-2027

    • 7.3.5.2 Market size analysis, By Model, 2020-2027

  • 7.3.6 Rest of Asia-Pacific

    • 7.3.6.1 Market size analysis, By Disease Type, 2020-2027

    • 7.3.6.2 Market size analysis, By Model, 2020-2027

  • 7.3.7 Research Dive Exclusive Insights

    • 7.3.7.1 Market attractiveness

    • 7.3.7.2 Competition heatmap

• 7.4 LAMEA

  • 7.4.1 Brazil

    • 7.4.1.1 Market size analysis, By Disease Type, 2020-2027

    • 7.4.1.2 Market size analysis, By Model, 2020-2027

  • 7.4.2 Saudi Arabia

    • 7.4.2.1 Market size analysis, By Disease Type, 2020-2027

    • 7.4.2.2 Market size analysis, By Model, 2020-2027

  • 7.4.3 UAE

    • 7.4.3.1 Market size analysis, By Disease Type, 2020-2027

    • 7.4.3.2 Market size analysis, By Model, 2020-2027

  • 7.4.4 South Africa

    • 7.4.4.1 Market size analysis, By Disease Type, 2020-2027

    • 7.4.4.2 Market size analysis, By Model, 2020-2027

  • 7.4.5 Rest of LAMEA

    • 7.4.5.1 Market size analysis, By Disease Type, 2020-2027

    • 7.4.5.2 Market size analysis, By Model, 2020-2027

  • 7.4.6 Research Dive Exclusive Insights

    • 7.4.6.1 Market attractiveness

    • 7.4.6.2 Competition heatmap

8. Competitive Landscape

• 8.1 Top winning strategies, 2020-2027

  • 8.1.1 By strategy

  • 8.1.2 By year

• 8.2 Strategic overview

• 8.3 Market share analysis, 2020-2027

9. Company Profiles

• 9.1 Bristol-Myers Squibb Company

  • 9.1.1 Overview

  • 9.1.2 Business segments

  • 9.1.3 Product portfolio

  • 9.1.4 Financial performance

  • 9.1.5 Recent developments

  • 9.1.6 SWOT analysis

• 9.2 Abbott Laboratories

  • 9.2.1 Overview

  • 9.2.2 Business segments

  • 9.2.3 Product portfolio

  • 9.2.4 Financial performance

  • 9.2.5 Recent developments

  • 9.2.6 SWOT analysis

• 9.3 Novartis AG

  • 9.3.1 Overview

  • 9.3.2 Business segments

  • 9.3.3 Product portfolio

  • 9.3.4 Financial performance

  • 9.3.5 Recent developments

  • 9.3.6 SWOT analysis

• 9.4 Sun Pharmaceuticals Industries Ltd

  • 9.4.1 Overview

  • 9.4.2 Business segments

  • 9.4.3 Product portfolio

  • 9.4.4 Financial performance

  • 9.4.5 Recent developments

  • 9.4.6 SWOT analysis

• 9.5 Pfizer Inc

  • 9.5.1 Overview

  • 9.5.2 Business segments

  • 9.5.3 Product portfolio

  • 9.5.4 Financial performance

  • 9.5.5 Recent developments

  • 9.5.6 SWOT analysis

• 9.6 Vectura Group plc

  • 9.6.1 Overview

  • 9.6.2 Business segments

  • 9.6.3 Product portfolio

  • 9.6.4 Financial performance

  • 9.6.5 Recent developments

  • 9.6.6 SWOT analysis

• 9.7 GlaxoSmithKline plc

  • 9.7.1 Overview

  • 9.7.2 Business segments

  • 9.7.3 Product portfolio

  • 9.7.4 Financial performance

  • 9.7.5 Recent developments

  • 9.7.6 SWOT analysis

• 9.8 Mylan N.V.

  • 9.8.1 Overview

  • 9.8.2 Business segments

  • 9.8.3 Product portfolio

  • 9.8.4 Financial performance

  • 9.8.5 Recent developments

  • 9.8.6 SWOT analysis

• 9.9 Sanofi

  • 9.9.1 Overview

  • 9.9.2 Business segments

  • 9.9.3 Product portfolio

  • 9.9.4 Financial performance

  • 9.9.5 Recent developments

  • 9.9.6 SWOT analysis

• 9.10 F. Hoffman-La-Roche Ltd.

  • 9.10.1 Overview

  • 9.10.2 Business segments

  • 9.10.3 Product portfolio

  • 9.10.4 Financial performance

  • 9.10.5 Recent developments

  • 9.10.6 SWOT analysis